Amgen is collaborating with Xencor, Inc. to expand on our own pioneering work in target discovery, protein therapeutics, and bispecific and multispecific antibodies with the XmAb® antibody platform.1 XmAb® technology is an investigational immunomodulatory platform consisting of engineered fragment crystallizable (Fc) domains with selective high affinity binding to create half-life extended T cell engagers, dual-targeting bispecific antibodies, and multispecific antibodies.1 Multispecific antibodies can be designed with 2 variable domains that require simultaneous binding to 2 tumor-antigen-binding domains, and a CD3-binding domain.1
The XmAb® Fc domain technology is designed to maintain full-length antibody properties in a bispecific antibody, with the goal of enabling favorable in vivo half-life and simplified manufacturing. These bispecific antibodies are designed to activate T cells at the site of the tumor to fight malignant cells.
Search our clinical trials.
Visit our resources section for further information on modalities currently under investigation.
XmAb® is a registered trademark of Xencor, Inc.
1. Moore GL, Bernett MJ, Rashid R, et al. Methods. 2019;154:38-50.